Top Abstract Purchase Related
Home
>
Node
>
Subnode

Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications

Giannoukakis, N.

Current Opinion in Investigational Drugs 7(10): 916-923

2006

ISSN/ISBN: 1472-4472
PMID: 17086937
Document Number: 602419
Ranirestat is an orally available aldose reductase inhibitor under development by Dainippon Sumitomo Pharma Co Ltd (formerly Dainippon Pharmaceutical Co Ltd), Kyorin Pharmaceutical Co Ltd and Eisai Co Ltd for the potential treatment of diabetic complications, such as neuropathy, cataracts, retinopathy and nephropathy. Phase III trials were ongoing in February 2006.

Document emailed within 1 workday
Secure & encrypted payments

Gervasi, G.B.; Bartoli, C.; Catalani, R.; Farina, C.; Carpita, G.; Caccia, G.; Ammannati, P. 1991: Effects of a new aldose reductase inhibitor on diabetic complications in rats Arzneimittel-Forschung 41(11): 1160-1163
Terranova, R.; Luca, S. 1993: Treatment with an aldose reductase inhibitor in peripheral neuropathy in elderly diabetic patients Minerva Medica 84(9): 461-466
Kojima, K.; Matsubara, H.; Harada, T.; Mizuno, K.; Suzuki, M.; Hotta, N.; Kakuta, H.; Sakamoto, N. 1985: Effects of aldose reductase inhibitor on retinal microangiopathy in streptozotocin-diabetic rats Japanese Journal of Ophthalmology 29(1): 99-109
Varma, S.D. 1986: Inhibition of aldose reductase by flavonoids: possible attenuation of diabetic complications Progress in Clinical and Biological Research 213: 343-358
Kofo-Abayomi, A.; Lucas, P.D. 1987: Muscarinic receptor density is reduced in diabetic rat atria, an effect prevented by the aldose reductase inhibitor, Statil Journal of Pharmacy and Pharmacology 39(12): 1019-1021
Nakamura, J.; Itoh, S.; Kani, K.; Okamoto, R. 1998: Metabolic changes of aldose and phosphorus metabolites in incubated rabbit lenses--effects of aldose reductase inhibitor Nippon Ganka Gakkai Zasshi 102(9): 561-569
Dent, M.T.; Tebbs, S.E.; Gonzalez, A.M.; Ward, J.D.; Wilson, R.M. 1991: Neutrophil aldose reductase activity and its association with established diabetic microvascular complications Diabetic medicine: a journal of the British Diabetic Association 8(5): 439-442
Cotter, M.A.; Cameron, N.E.; Hohman, T.C. 1998: Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats Journal of the Peripheral Nervous System: Jpns 3(3): 217-223
Yue, D.K.; Brooks, B. 1993: The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy Medical Journal of Australia 159(2): 76-78
Wright, M.; Hill, S.; Slaney, M.A. 1994: The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy Medical Journal of Australia 160(1): 45
Kador, P.F.; Sharpless, N.E. 1983: Pharmacophor requirements of the aldose reductase inhibitor site Molecular Pharmacology 24(3): 521-531
Erkelens, D.W.; Bravenboer, B. 1990: Aldose reductase inhibitors in diabetic neuropathy Nederlands Tijdschrift Voor Geneeskunde 134(15): 775-776
Parmar, N.S.; Ghosh, M.N. 1981: Lens aldose reductase in diabetic and galactosemic cataracts Indian Journal of Physiology and Pharmacology 25(3): 193-200
Terubayashi, H.; Akagi, Y. 1989: The effect of aldose reductase inhibitor, statil, on hyperpermeability of iridial vessels in experimental galactosemic rats Japanese Journal of Ophthalmology 33(3): 343-347
Kador, P.F.; Akagi, Y.; Kinoshita, J.H. 1985: Diabetic cataracts in animal models: prevention and reversibility with aldose reductase inhibitors Diabetic Medicine: a Journal of the British Diabetic Association 2(3): 194-196
Peppard, W.J.; Schuenke, C.D. 2008: Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections Current Opinion in Investigational Drugs 9(2): 210-225
Ansari, N.H.; Bhatnagar, A.; Liu, S.Q.; Srivastava, S.K. 1991: Purification and characterization of aldose reductase and aldehyde reductase from human kidney Biochemistry International 25(4): 755-765
Kotyla, P.J.; Sliwinska-Kotyla, B.; Kucharz, E.J. 2006: Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin Journal of rheumatology 33(11): 2361-3; author reply 2363
Hamada, Y. 2004: Aldose reductase Nihon Rinsho. Japanese Journal of Clinical Medicine 62(Suppl 11): 448-451
Futterman, L.G.; Lemberg, L. 2005: The expanding role of the HMG-CoA reductase inhibitor, the most widely prescribed drug in the world American Journal of Critical Care: An Official Publication American Association of Critical-Care Nurses 14(6): 555-558